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Abstract Several apolipoproteins including apoE and apoA-I 
are known to be associated with amyloid ~peptide, a major 
component of senile plaques in Alzheimer's disease. In the 
present study the interaction between three human amphipathic 
apolipoproteins apoE3, apoA-I and apoA-1I and immobilized 
amyloid ~i-peptide (1-40) was quantified by plasmon resonance. 
The interactions were saturable and reversible. The results 
demonstrated a high affmity of the binding of amphipathic 
apolipoproteins to amyloid ~peptide. On the other hand, only a 
small population of synthetic amyloid ~peptide participated in 
the interaction. The apparent equilibrium dissociation constants 
/fD were 10 nM for apoE3, 25 nM for apoA-I and 80 nM for 
apoA-II under physiological conditions. The affinity of the 
apoE3-amyloid ~-peptide binding was not affected by pH in the 
range 6.0-8.0 but was significantly increased by high salt 
concentration. ApoA-I mainly followed similar patterns. A major 
participation of hydrophobic forces in the binding of apoE3 and 
apoA-I to amyloid ~-peptide was suggested. 
.~(ey words: Alzheimer's disease; Amyloid beta-protein; 
Apolipoprotein E; Apolipoprotein A-I; Apolipoprotein A-II; 
Protein binding 
I. Introduction 
Apolipoprotein E (apoE) is a key protein in the plasma 
l~pid-transport system and an important cholesterol-transport 
i,rotein in the brain. Human apoE is a polymorphic 34-kDa 
t~rotein which has 3 common isoforms: ancestral apoE4, 
~poE3, the most common isoform, and apoE2 [1-3]. The 
~tpoE gene has been linked to Alzheimer's disease (AD) as a 
~;enetic risk factor due to the increased E4 allele frequency 
round among patients with late-onset familial and sporadic 
\D [4]. However, the mechanism by which e4 allele increases 
The risk of AD is still unknown. 
In vitro, apoE binds in isoform-specific manner with 'high 
tvidity' to amyloid 13-peptide (A[~), a major protein compo- 
lent of the senile plaques [5]. AI3 is a small fragment of 3943 
amino acid residues from a transmembrane glycoprotein, the 
tmyloid precursor protein [6]. Most of the biological fluids, 
ncluding cerebro-spinal fluid and plasma, contain a soluble 
orm of A~, mainly A[3(1-40), with secondary structure dis- 
inct from A~ in amyloid deposits. AI3 of amyloid deposits has 
I-sheet structure while soluble A[~ demonstrates random coils 
md c~-helical structures [7,8]. 
"Corresponding author. Fax: (33) (83) 32 13 22. 
4bbreviations: Apo, apolipoprotein(s); AD, Alzheimer's disease; AI3 , 
amyloid 13-peptide; SPR, surface plasmon resonance; KD, equilibrium 
dissociation constant; kdiss , kass, rate constants of dissociation and 
association, respectively; RU, refractive units. 
Several proteins including apoE and apoA-I were co-loca- 
lized with A[3 in senile plaques. Moreover, it has recently been 
shown that numerous proteins can bind to synthetic AI3 in 
vitro, such as apoJ, apoE, apoA-I, apoA-II, amyloid P com- 
ponent, transthyretin and others [9-13]. The binding of A~ 
with these proteins is under extensive investigation due to its 
possible involvement in the pathogenesis of AD. It was sug- 
gested that apoJ, transthyretin and apoE may play a role in 
soluble AI3 transport or in the formation of AI3 fibrils 
[6,10,14,15], while a possible role of apoA-I and apoA-II in 
AI3 turnover is not clear yet. Nevertheless, the binding of 
apoE and other amphipathic apolipoproteins to AI3 has not 
yet been quantified. In this work we have quantitatively as- 
sessed and investigated the binding of human apoE3, apoA-I 
and apoA-II to AI3(1M0) by surface plasmon resonance 
(SPR). SPR, an analytical system based on biosensor technol- 
ogy, allowed characterization of biospecific interactions of 
label-free compounds [16,17]. The binding kinetics and affinity 
of AI3 interactions with human apoA-I and apoA-II, impor- 
tant protein components of lipoproteins in plasma and cere- 
bro-spinal fluid, were studied for comparison with apoE since 
all these apoproteins have similar amphipathic nature [18,19]. 
Neither apoA-1 nor apoA-II has an effect on assembly of 
A13(1-42) into filaments, in contrast o apoE [20]. However, 
levels of both apolipoproteins were decreased in plasma of 
late-onset AD patients [9,21]. We showed that these apolipo- 
proteins bound to AI3 with high affinity, with apoE3 having 
the highest affinity. The effects of pH and salts on the binding 
of the apolipoproteins to A[3 suggest that hydrophobic forces 
predominantly participate in the apoE-A[3 and apoA-I-AI3 
interactions. 
2. Materials and methods 
2.1. Materials 
Synthetic A~(1-40) (lot 506063) was purchased from Bachem (Swit- 
zerland). Sensor chips CM5, 100 rnM N-ethyl-N'-(3-dimethylamino- 
propyl)carbodiimide, 400 mM N-hydroxysuccinimide and1.0 M etha- 
nolamine (pH 8.5) were obtained from Pharmacia Biosensor 
(Sweden). Bovine albumin (essentially fatty acid free) and guanidine 
were obtained from Sigma (USA). 
2.2. Purification of human apolipoproteins 
ApoE was purified from human plasma very low density lipopro- 
teins of normal e3/e3 individuals. Very low density lipoproteins were 
obtained by ultracentrifugation at a density 1.006 g/ml and were de- 
lipidated in ethanol:diethyl ether mixtures and dissolved in 6 M gua- 
nidine-HC1. ApoE was isolated by gel filtration on Sepharose CL-6B 
in 10 mM Tris-HCl (pH 8.0), 1 mM dithiotreitol with 4 M guanidine- 
HCI and affinity chromatography on heparin-Sepharose in 0.15 M 
NaCI, 1 mM EDTA, 0.02% sodium azide, 10 mM Tris-HC1 (pH 
7.4) [22]. Apolipoproteins A-I and A-II were purified from human 
plasma high density lipoproteins, isolated by ultracentrifugation 
over the density range 1.065-1.21 g/ml. High density lipoproteins 
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were delipidated in chloroform/methanol 2:1. Apolipoproteins were 
isolated by gel filtration on Toyopearl HW-55F and then separated by 
anion-exchange chromatography on DEAE-Toyopearl 650M in 6 M 
urea [23]. All purified proteins howed a single band on SDS electro- 
phoresis [24]. 
2.3. Immobilization of A~ on sensor chip 
AI3(1-40) was dissolved in deionized water to a concentration of 
1 mg/ml, and small aliquots were frozen until use. SPR studies were 
performed on BIAlite apparatus (Pharmacia Biosensor). The immo- 
bilization protocol mainly followed the recommendations of the man- 
ufacturer. A sensor chip was activated by a misture of 100 mM 
N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride/400 
mM N-hydroxysuccinimide mixture 1 : 1 (v/v), to allow the subsequent 
covalent cross-linking of the injected peptide through primary amine 
groups. Then 35 ml of 50 mg/ml AI3 in 10 mM acetate buffer (pH 4.0) 
was injected at a flow rate of 5 ml/min and unreacted active sites were 
blocked with 1.0 M ethanolamine, pH 8.5. After immobilization, on- 
specifically bound A~ was removed with 4 M guanidine-HCl, 10 mM 
Tris-HCl (pH 8.0). Since 1000 resonance units (RU) determined by 
SPR corresponds 1.0 pg/mm 2 of bound ligand, the total immobilized 
mass of AI3 under these conditions was approx. 7.0 pg/mm 2. 
2.4. Surface plasmon resonance xperiments 
All binding experiments were performed at 25°C and at a flow rate 
of 5 ml/min. 30 ml of protein in running buffer (10 mM phosphate 
buffer, 0.15 M NaC1, pH 7.4) were injected for association (contact 
time 6 min). Dissociation was followed in the same buffer for 6 rain. 
After each run, the sensor chip was regenerated with 10 ml of 4 M 
guanidine-HCl, 10 mM Tris-HC1, pH 8.0 (contact ime 2 min) and 
washed with running buffer for 5-10 min prior the next injection. In 
some experiments he pH varied from 6.0 to 8.75 or NaCI concentra- 
tion varied up to 1.0 M. All buffers were filtered through 0.22 mm 
filters (Millipore, USA) and degassed before use. The injection system 
was rinsed to change one buffer for another when necessary. 
Rate association and dissociation constants k~s and kdiss and other 
kinetic parameters for apolipoproteins were estimated by the BIAeva- 
luation software (Pharmacia Biosensor) using the model A + B = AB to 
fit the data. The dissociation rate constant was calculated as the slope 
of a curve using the log of the drop in response during dissociation 
phase against ime interval n(Ro/R) = kd iss ( t  - -  to), where Ro is the re- 
sponse at an arbitrarily chosen starting time to, and R is the response 
at current ime t. The association rate constant was calculated from 
the log transformation f the association phase ln(dR/dt) against time in 
accordance to the equation ln(dR/dt)= ln(ka~CRma~)-(kas~C+ kd iss ) l ,  
where C is the molar concentration of analyte, Rm~ is the maximal 
response, and kdi~ is the known rate dissociation constant. KD was 
calculated as the ratio k~i~/k~. 
3. Results 
The binding of apoA-I, apoA-II,  apoE3, and albumin used 
as a control protein, to AI3 was studied in I0 mM phosphate 
buffer, 0.15 M NaC1, pH 7.4. All apolipoproteins readily 
bound to AI3 whereas albumin did not (Fig. 1). Obviously, 
the interactions between the apolipoproteins and AI3 were 
saturable and reversible. In the representative experiment, 
maximal response Rm~ calculated from association phase 
was 440 RU for apoE3, 400 RU for apoA-I, and 210 RU 
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Fig. 1. Kinetic binding curves (sensorgrams) of apolipoprotein and 
albumin binding to A(3(140) in 10 mM phosphate buffer, 0.15 M 
NaC1, pH 7.4. ApoE3 was at a concentration of 35 mg/ml (1 mM), 
apoA-I, apoA-II and albumin being at a concentration of 50 mg/ml 
(1.8, 2.9 and 0.8 mM, respectively). The binding curves are ex- 
pressed as resonance units (RU) as a function of time. The spikes 
indicate the beginning of the dissociation phase. A total of 7200 
RU of AI3 was immobilized. 
for apoA-II. It corresponds to the maximal binding, for ex- 
ample, of 0.44 pg/mm 2 of apoE on a sensor chip which con- 
tainted 7.2 pg/mm 2 of immobilized A[3. The maximal molar 
ratios were estimated as apoE:AI3 1:130, apoA-I:Al~ 1:120, 
and apoA-II:AI3 1:90 under these experimental conditions. 
Thus, only a minor population of the synthetic AI3(1-40) 
was able to interact with these apolipoproteins on the time 
scale of minutes. To assess the kinetic binding constants of 
apolipoprotein binding with immobilized AI3 under physiolo- 
gical conditions, samples of apolipoproteins were injected on 
immobilized A~ in increasing concentrations (0.13-1.0 mM 
for apoE3, 0.22-1.78 mM for apoA-I, and 0.36-2.87 mM 
for apoA-II) as shown in Fig. 2. Table 1 shows rate constants 
and equilibrium dissociation constants of apolipoprotein-AI3 
binding. ApoE3 has the highest affinity for AI3 among these 
three amphipathic apolipoproteins. ApoE3 showed an asso- 
ciation rate close to that of apoA-I, but the dissociation rate 
for apoE3 was significantly lower. In spite of having the low- 
est affinity of apoA-II  for AI3 among the apolipoproteins stud- 
ied, apoA-II  still showed strong binding to AI3. 
The binding of apolipoproteins to AI~ was carried out at 
different pH values in 10 mM phosphate buffer, containing 
0.15 M NaC1. ApoE3 was used at a concentration of 35 mg/ 
ml (1.0 mM), ApoA-I  and apoA-II  were at a concentration of 
50 mg/ml (1.8 and 2.9 mM, respectively). It was demonstrated 
that the pH, in the range 6.0--8.0, did not change significantly 
either the equilibrium dissociation constant KD (Fig. 3A) or 
the maximal binding Rm~x (data not shown) of apoE3 and 
apoA-I interactions with A~. A tendency for increasing KD 
at pH 8.75 was observed. Rate constants also were not sig- 
Table 1 
Kinetic binding constants of interactions between apolipoproteins and immobilized AI3 
Apolipoprotein k~s (s -1 M -1) (x  10 -3) kdiss (S -1) (X 10 4) KD (nM) 
ApoE3 25.6 _+ 15.1 2.09 4- 0.55 10.0 4- 4.6 
(n = 7) (n = 8) (n = 7) 
ApoA-I 27.7 4- 13.5 5.69 4- 0.60 25.0 + 10.0 
(n = 5) (n = 6) (n = 5) 
ApoA-II 10.1 4- 3.0 6.65 4- 1.12 79.0 + 22.0 
(n = 3) (n = 6) (n = 3) 
The buffer contained 10 mM PBS, 0.15 NaC1 (pH 7.4). Mean+ SD are shown. 
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F g. 2. Binding of human apoE3 to A~(I~0). Kinetic binding 
c~ ryes. ApoE3 concentrations are given to the right of each trace in 
n~ tcromolarity. 
n fcantly changed in this range of pH (data not shown). On 
the other hand, the affinity of apoA-II-AI3 binding continu- 
oasly decreased as pH increased from 6.0 to 8.75 (Fig. 3A), 
d ae to changes of k~. 
The effects of NaC1 were studied in 10 mM phosphate buf- 
fir (pH 7.4). The concentrations of the apolipoproteins used 
ere as indicated in pH experiments. It was shown that KD 
f,,r apoE3-A~ interaction was drastically decreased at high 
blaCl concentration (Fig. 3B). This significant increase of 
a lgoE3-A[3 binding affinity was in a major part due to a de- 
c'ease in kdiss. On the other hand, the maximal binding R,~x 
decreased as well. NaC1 also decreased the KD of binding of 
apoA-I and apoA-II to AI3 (Fig. 3B). This was due to a mild 
increase of k~ for apoA-I and changes of both rate constants 
f ~r apoA-II. 
4. Discussion 
The present work demonstrates that human apoE, apoA-I 
~ nd apoA-II bind to immobilized AI3 with high affinity on the 
tme scale of minutes, whereas albumin as a control protein 
~id not bind. The interaction between these apolipoproteins 
~nd AI] was saturable and reversible. The calculated Ko va- 
lies were 10 nM for apoE3, 25 nM for apoA-I and 80 nM for 
~.poA-II. ApoJ was shown to have high affinity for AI](1-40) 
I KD 2 nM by ELISA). All three isoforms of apoE demon- 
~trated signifcant ability to inhibit apoJ-A[3(1-40) complex 
~ormation and apoE3 was only 6.5 times less efficient than 
poJ itself [25]. Thus, the KD of apoE-AI3 binding obtained 
~>y SPR was in good agreement with indirect ELISA data. At 
~ae protein concentrations used in the assay (5-50 mg/ml), 
!,oth apoA-I and apoA-II are predominantly monomeric 
26,27], while apoE is mainly tetrameric [28,29]. Nevertheless, 
nalysis of the dissociation phase for apoE-AI3 complex indi- 
, ated a closely fitting correspondence to a 1:1 complex dis- 
ociation model under the experimental conditions, suggesting 
~he absence of allosteric effects. 
We estimated that, under our experimental conditions, the 
binding showed maximum ratios of apo's to A[3 of about 
:100 mol/mol. Although this ratio may apparently depend 
, ,n the source of All and other conditions [30], it is clear 
hat  only a small fraction of the immobilized AI] molecules 
are able to bind to apoE on the minute time scale, as followed 
hy SPR. These results confirm the importance of the confor- 
~nation of A[3 on binding. 
The binding of apoE3 to AI3 was not significantly affected 
n the pH 6.0-8.0 range, while high salt concentrations sig- 
nificantly increased the binding affinity. The latter effect was 
mainly due to a decreased issociation rate of the apoE-AI3 
complexes in highly polar buffer. The effects of pH and po- 
larity of the buffer were suggested to reflect the major parti- 
cipation of hydrophobic forces in the apoE-A[3 interaction. 
ApoE has the N-terminal receptor-binding domain and C- 
terminal domain responsible in major part for lipid binding 
[28]. Apparently, the AI3-binding site of apoE is localized in 
lipid-binding sites. Indeed, delipidation of apoE increases the 
'avidity' of apoE-A[3 binding in comparison with lipid-bound 
apoE [31], indicating the involvement of lipid-binding sites of 
apoE in the interaction with AI3. Moreover, it was shown that 
the C-terminal fragment of apoE 244-272 was critical for 
formation of apoE-AI3 complexes and the C-terminal domain 
of apoE was co-purified with A[3 from senile plaques [5,32]. 
However, the mechanism of the apoE-A[3 binding remains to 
be elucidated. 
The major involvement of hydrophobic forces was also sug- 
gested for apoA-I-A[3 but not for the apoA-II-AI3 interaction. 
The binding of apoA-II to AI3 was affected by pH, indicating 
significant involvement of other forces in the interaction as 
well as hydrophobic forces. We suggested that apoA-I may 
play a role in AD pathogenesis due to its high affinity binding 
to A[3. 
The SPR technique used in this study is a powerful tool to 
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Fig. 3. Effect of pH (A) and NaC1 (B) on the equilibrium dissocia- 
tion constants KD of the interaction of apoE3 (open boxes), apoA-I 
(closed boxes) and apoA-II (crosses). The effect of pH was studied 
in 10 mM phosphate buffer, 0.15 M NaC1 and that of NaCI in 10 
mM phosphate buffer (pH 7.4). 
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useful to study the effects of apoE and A~ polymorphism and 
to determine potential agents or protein modifications which 
are able to modulate the interactions. 
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